ObsEva SA (OBSV) News
Filter OBSV News Items
OBSV News Results
|Loading, please wait...|
OBSV News Highlights
- OBSV's 30 day story count now stands at 11.
- Over the past 16 days, the trend for OBSV's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- SA, MS and INZY are the most mentioned tickers in articles about OBSV.
Latest OBSV News From Around the Web
Below are the latest news stories about ObsEva SA that investors may wish to consider to help them evaluate OBSV as an investment opportunity.
With the long weekend over it's time to start another week of trading with the biggest pre-market stock movers for Tuesday!
If you want to know who really controls ObsEva SA ( NASDAQ:OBSV ), then you'll have to look at the makeup of its share...
ObsEva (OBSV) signed a licensing agreement with Theramex to support the commercialization and market introduction of linzagolix in markets outside of the U.S., Canada and Asia.OBSV…
- Partnership leverages Theramex’s leading women’s health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets outside of the U.S., Canada and Asia - - Linzagolix is an oral GnRH antagonist in development for the management of moderate to severe symptoms of uterine fibroids and endometriosis-associated pain - Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland, Feb. 10, 2022 (G
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA (OBSV – Research Report), Inozyme Pharma (INZY – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments. ObsEva SA (OBSV) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA today and set a price target of $15.00. The company's shares closed last Friday at $1.43, close to its 52-week low of $1.35. According to TipRanks.
ObsEva SA (NASDAQ: OBSV ) said that based on ongoing communications with the European Medicines Agency (EMA), it expects further questions on the linzagolix application, thereby extending the application timeline . ObsEva is in dialogue with the EMA to understand areas that may require further clarification and is committed to promptly addressing any questions that could arise. In December, EMA''s Committee for Medicinal Full story available on Benzinga.com
ObsEva (NASDAQ:OBSV) is trading ~5% lower in the post-market on Friday after the company announced that its European marketing authorization for linzagolix could extend. Linzagolix is a once-daily, oral GnRH receptor antagonist which has undergone late-stage trials for uterine fibroids. Based on the ongoing discussions with the European Medicines Agency (EMA), the...
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 4, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that based on ongoing communications with the European Medicines Agency (EMA), further questions on the marketing authorisation application for linzagolix may be forthcoming, thereby extending the application timeline. ObsEva is in dialogue w
ObsEva (NASDAQ:OBSV) is trading ~7% higher in the pre-market on above-average volume after announcing the appointment of Katja Buhrer as its Chief Strategy Officer and member of the company’s Executive Committee effective Feb. 01. About 3.7M company shares have changed hands so far, compared to the 65-day average of ~908.0K shares. Ms....
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeGENEVA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Katja Buhrer as Chief Strategy Officer and member of the company’s Executive Committee, effective February 1, 2022. Ms. Buhrer will oversee a range of operational areas including corporate strategy, investor relations and p